medigraphic.com

2012, Number 2

<< Back Next >>

Rev Latinoam Psiquiatría 2012; 11 (2)

Fenproporex en el tratamiento de la obesidad y la hiperfagia por estrés

Verduzco FW

Language: Spanish
References: 62
Page: 46-51
PDF size: 163.32 Kb.


ABSTRACT

Background: The use of drugs for the treatment of obesity is object of great debate. Following the ban on amphetamines, fenproporex (3 - [1-methyl-2-phenylethylamine] propionitrile) is one of the first molecules developed as a substitute due to its anorexigenic action. Despite its addictive potential, it is currently used in many countries. It has been suggested that its combination with diazepam could improve the efficacy due to the significant association between stress and hyperphagia as causes of obesity.
Objective: Define the current role of fenproporex as a pharmacological alternative for the treatment of obesity and its combination with diazepam in the treatment of hyperphagia due to stress.
Methodology: An automated search was carried out in OVID with the key words fenproporex, diazepam, polyphagia, stress, obesity and mental health. Sixty-three articles were chosen.
Results: There is evidence in medical literature supporting the use of fenproporex in combination with diazepam for the treatment of obesity.
Conclusions: Although the use of these formulations is still controversial, factors such as clinical experience, a broad knowledge about their action mechanism and the patient profile, are crucial for its prescription. Patients should be controlled and monitored periodically by the clinician in order to avoid misuse and potential serious adverse effects.


REFERENCES

  1. Morín R, Ponce ML, Lonngi S, Alcaraz R, Lonngi G. Eficacia y seguridad de dos formulaciones de fenproporex de liberación lenta como tratamiento de obesidad. Rev Mex Cardiología 2005;16(4):146–154.

  2. Pe´lissier-Alicot AL, Piercecchi-Marti MD, Bartoli C, Kuhlmann E, Coiffait PE, Sanvoisin A, Giocanti D, Le´onetti G. Abusive Prescription of psychostimulants: A study of two cases. J Forensic Sci 2006;51(2):407-410.

  3. The Practical guide to the identification, evaluation and treatment of overweight and obesity in adults. Bethesda, Maryland: NIH; Publication number 00-4084, 2000.

  4. Goldstein DJ, Potvin JH. Long-term weight loss: the effect of pharmacologic agents. Am J Clin Nutr 1994; 60:647-657.

  5. Silverstone T. Appetite suppressants. Drugs 1992; 43:820-836.

  6. Warembourg H, Jaillard J. Expérimentation clinique du fenproporex dans le traitement des obesites. Lille Medical 1968;13: 273-276.

  7. Hensrud DD. Farmacoterapia para la obesidad. Clin Med Norteamérica 2000;2:455-466.

  8. Baumevieille M, Haramburu F, Bégaud B. Abuse of prescription medicines in southwestern France. Ann Pharmacother 1997;31:847-850.

  9. Cody JT. Precursor medications as a source of methamphetamine and/or amphetamine positive drug testing results. J Occupat Environm Medicine 2002;44(5):1-25.

  10. Kraemer T, Pflugmann T, Bossmann M, Kneller NM, Peters FT, Paul LD, Springer D, Staack RF, Maurer HH. Fenproporex N-dealkylation to amphetamine—enantioselective in vitro studies in human liver microsomes as well as enantioselective in vivo studies in Wistar and Dark Agouti rats. Biochem Pharm 2004;(68):947–995.

  11. Musshoff F. Illegal or legitimate use? Precursor compounds to amphetamine and methamphetamine. Drug Metab Rev. 2000;32(1):15–44.

  12. Soulairac A. Etude electroencephalographique et statokinesimetrique du perphoxene chez l’homme. Therapeutique 1971;47: 365-369.

  13. Luquero F. Tratamiento de la obesidad con un nuevo fármaco lipolítico y anorexigénico: el fenproporex. Rev Esp Ap Resp 1971;34:91-98.

  14. Faivre G, Dodinot B, Hua G. Traitement de l’obesite chez les cardiaques experimentation d’un nouvel anorexigene. La Vie Medicale 1969;2:730-734.

  15. Rodrigues AM, Bento B, de Lacerda H, Monteiro De Almeida S, Artigas Patricia, Boguszewski CL. The Cerebrospinal Fluid/ Serum Leptin Ratio during Pharmacological Therapy for Obesity. J. Clin Endocrinol Metab 2002; 87:1621-1626, doi: 10.1210/jc.87.4.1621

  16. Silva O, Yonamine M, Antunes C, Greve J, Midio A. Fenproporex abuse by truck drivers in Brazil. www.tiaft.org/tiaft98/thu/p/t_p_32.html.

  17. Moreira CQ, Faria MJ, Moreira EG. Behavioral neurotoxicity in adolescent and adult mice exposed to fenproporex during pregnancy. Human Exp Toxicol 2005;24:403-408.

  18. Moreira CQ, Faria MJ, Baroneza JE, Oliveira RJ, Moreira EG. Developmental exposure to fenproporex: reproductive and morphological evaluation. Human Exp Toxicol 2005;24:397-402.

  19. Plauchu MM, Arnaud M, Pousset G. Etude clinique d'un nouvel anorexigéne, Lyon Med 1968;(14):111-116.

  20. Vague J, Codaccioni JL, Kelisbauer JP. Etude clinique chez 44 obeses d'un nouvel anorexigéne actif par voie buccale: le fenproporex. Sud Med Chirurg 1967;2:541-545.

  21. Tognoni G, Morselli PL, Garattini S. Amphetamine concentrations in rat brain and human urine after fenproporex administration. Eur J Pharmacol 1972;(20):125-126.

  22. Beckett AH, Shenoy EVB, Salmon JA. The influence of replacement of the N-ethyl groups by the cyanoethyl group on the absorption, distribution and metabolism of (I) ethyl amphetamine in man. J Pharm Pharmacol 1972;24(3):194- 202.

  23. Munro JF. Clinical aspects of the treatment of obesity by drugs: a review. Int J Obesity 1979;3:171-80.

  24. Galloway S, Fuqua D, Munro JF. The current status of antiobesity drugs. Postgr Med J 1984;60(Suppl. 3):19-26.

  25. Scoville BA. Review of amphetamine-like drugs by the Food and Drug Administration: clinical data and value judgement. In: Bray GA, editor. Obesity in perspective. DHEW Publ. No. (NIH) 75-708, Bethesda (MD): National Institutes of Health,1975:441-443.

  26. Rall T, Schleifer L. Fármacos efectivos en el tratamiento de la epilepsia. Bases Farmacológicas de Terapéutica. Goodman y Guillman, 8a Ed. Panamericana. 1991:433-457.

  27. Morín R, Lonngi G, Alcaraz R, Rosas D. Comparación de dos formulaciones de d-norpseudoefedrina y placebo en pacientes obesos tratados durante seis meses. Med Int Mex 2001;17:260-271.

  28. Verduzco W, Platas C. Obesidad y Salud Mental. Psiquiatría 1999;5(3):49-55.

  29. Villaseñor SJ, Ontiveros C, Cárdenas KV. Salud mental y obesidad. Inv Salud 2006;8(2):86-90.

  30. Greeno C, Wing R. Stress-induced eating. Psychol Bull 1994,15(3):444-464.

  31. Morley JE, Levine AS, Rowland NE. Stress inducing eating. Life Sci, 1983;32:2169-2182.

  32. Shelley HP. Eating Behavior. Social facilitation or social inhibition? Psychonomic Sci 1965;3:521-522.

  33. Rowland NE, Antelman SM. Stress-induced hyperphagia and obesity in rats: A possible model for understanding human obesity. Science 1976;141(4224):310- 312.

  34. Schachter S, Goldman R, Gordon A. Effects of fear, food, deprivation and obesity on eating. J Personality Soc Psychology 1968;10:91-97.

  35. Vakhmistrov AV, Voznesenskaia TG, Posokhov SI. Clinical and psychological analysis of eating disorders in obesity. Vakhmistrov Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 2001;101(12):19-24(Abstract en ingles).

  36. Lazarevich I, Rodríguez JH. Manifestaciones psiquiátricas en los trastornos tiroideos, diabetes mellitus y obesidad. Psiquis 2003; 23(5):149-151.

  37. Newmana E, O’Connor DB, Conner M. Attentional biases for food stimuli in external eaters: Possible mechanism for stressinduced eating? Appetite 2008;51:339–342.

  38. Silva JR. Sobrealimentación inducida por la ansiedad. Parte I: Evidencia conductual, afectiva, metabólica y endocrina. Terapia Psicológica 2007;25(2):141-154.

  39. Kaplan H, Kaplan H. A Psychosomatic concept. Am J Psychother 1957;11:16-38.

  40. Bruch H. Transformation of oral impulses in eating disorders: A conceptual approach. Psychiatr Q 1961;35:458-481.

  41. Herman CP, Polivy J. Anxiety, restraint and eating behavior. J Abnor Psychology 1975;84:666-672.

  42. Herman CP, Polivy J. Restraint and excess and in dieters and in bulimics. In Pirke KM, Ploog D y Vandereycken W eds. Psychobiology of Bulimia, Berlín, Springer, 1988, pp 33-34.

  43. Polivy J, Herman CP. Distress and eating. Why Do dieters overeat? Intern J Eating Disord 1999;2:153-164.

  44. Haetherton T, Baumeister R. Binge-eaters as escape of selfawareness. Psychol Bull 1991;110:86-188.

  45. Wallis D, Hetherington M. Stress and eating: the effects of egothreat and cognitive demand on food intake in restrained and emotional eaters. Appetite 2004;43:39-46.

  46. Herman CP, Polivy J. Restrained eating. In: Stunkard A ed. Obesity. Philadelphia, Saunders, 1980, pp 208-225.

  47. Silva JR. Ansiedad y sobrealimentación. Investigación y Ciencia 2005;341:33-34.

  48. Lowe M, Kral T. Stress induced eating in restrained eaters may not be caused for stress or restraint. Appetite 2006;46:16-21.

  49. Grengrass JR, Harberd V, Field CJ, McCargar LJ. Metabolic assessment of female chornic dieters with either normal or low resting energy expenditures. Am J Clin Nutrition 2000;71:1413-1420.

  50. Weinstein SE, Shide DJ, Rolls BJ. Changes in food intake in response to stress in men and women: psychological factor. Appetite 1997;28:7–18.

  51. Wardle J, Waller J, Rapoport L. Body dissatisfaction and binge eating in obese women: the role of restraint and depression. Obes Res 2001;9:778–787.

  52. Roenmmich J, Wright SM, Epstein LH. Dietary restraint and stress-induced snacking in youth. Obes Res 2002;10:1120–1126.

  53. Francis JL. Psychosocial predictors of dietary fat reduction: the role of stress and the transtheoretical model in a dietary intervention. Department of Psychology, Louisiana State University, 2003.

  54. Paronis CA. Modulating GABA modulators. Br J Pharmacol 2006;147:237–238.

  55. Downing SS, Lee YT, Farb DH, Gibbs TT. Benzodiazepine modulation of partial agonist efficacy and spontaneously active GABA A receptors supports an allosteric model of modulation. Br J Pharmacol 2005;145:894–906.

  56. Vargas ML, Abella C, Hernández J. Diazepam increases the hypothalamic-pituitary-adrenocortical (HPA) axis activity by a cyclic AMP-dependent mechanism. Br J Pharmacol 2001;133:1355-1361.

  57. The APA Task Force Report on Benzodiazepine Dependence, Toxicity, and Abuse Am J Psychiatry 1991;148(2):151-153.

  58. Klotz U, Avmrr GR, Hoyumpa A, Sciemmum S, Wilkinson GR. The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Inv 1975; 55:347-359.

  59. Rossner S. Long-term intervention strategies in obesity treatment. Int J Obes Relat Metab Disord 1995;19(Suppl 7):29-33.

  60. Bray G, Ryan D, Gordon D, Heidigssfelder S, Cerise F, Wilson K. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res 1996;4:263-70.

  61. Davidson MH et al. Weigh control and risk factor reduction in obese subjects treated for 2 years with Orlistat. JAMA 1999;281:235-242.

  62. Kinell HG. European withdrawal of appetite suppressants. Obesity Rev 2003;4:79-81.




2020     |     www.medigraphic.com